According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...

Terns Pharmaceuticals reports its targeted leukemia drug maintained and even boosted molecular response rates in ...

Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...

An expert provided an overview of the promising therapies that are being investigated for the treatment of patients with chronic lymphocytic leukemia. There are many new agents being investigated for ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will present ...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...